Ivonescimab before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have head and neck cancer that can be removed with surgery (stage II–IV).
- Your tumor has a certain protein marker (PD-L1) that makes it more likely to respond to the study drug.
- You are generally healthy and able to do everyday activities (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within safe limits (checked by your doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two immunotherapy drugs (ivonescimab vs. pembrolizumab) given before and after surgery for head and neck cancer that can be surgically removed. The goal is to see which drug works better to shrink the tumor and prevent the cancer from coming back.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people with advanced mouth or throat cancer that can be removed with surgery. The goal is to see if the combination helps shrink tumors before surgery.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a new drug called Ivonescimab (AK112) combined with two chemotherapy drugs (Abraxane and cisplatin) given before surgery for esophageal cancer. The goal is to see if this combination can shrink tumors and improve surgery outcomes for patients with locally advanced disease.
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
This trial tests a new immunotherapy drug (ivonescimab) given before and after surgery, sometimes with chemotherapy, for people with operable non-small cell lung cancer. The goal is to see if it helps shrink tumors and keeps them from coming back.
Hear when a new Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.